I just reviewed the Tasigna approval time-line and it looks like their Phase 3 trial started in March 2006. The trial was stopped early and accelerated approval was granted in Oct 2007, basically 18 months from first enrollment. http://www.clinicaltrials.gov/ct2/show/NCT00302016?term=Nilotinib&rank=49
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.